Our study’s first objective was to investigate the expression of the CPSF4 protein in our unique TMAs cohort; this group was comprised of patients diagnosed with various prostate cancer stages, such as incidental, advanced, and castrate-resistant PCa (CRPCa). Here, CPSF4 is linked to prostate carcinoma.